Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say ...
The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...
An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.
An invited Guest Editorial entitled “Give Cas a Chance,” by Fyodor Urnov, PhD, Director of Technology & Translation at the ...
CRISPR technology allows for precise DNA modifications, holding promise for treating genetic disorders and revolutionizing ...
Given this risk, we thought we'd take a look at whether CRISPR Therapeutics (NASDAQ:CRSP) shareholders should be worried ...
Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...
7don MSN
In a potential advance for melanoma patients, researchers at ChristianaCare's Gene Editing Institute have used CRISPR gene ...
Have we entered the golden age of plant engineering?
EDT Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...
Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback